Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 2/2011

01.08.2011 | Original Article

The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations

verfasst von: Antonia Tsallas, John Jackson, Helen Burt

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Superficial bladder cancer occurs in the urothelial layer of the bladder and is usually treated by transurethral resection and chemotherapy. Although the bladder is well suited for intravesical chemotherapy, effective drug delivery is restricted by urine dilution and poor drug uptake by bladder tissues during a 2 h instillation. In this study, freshly excised pig bladder sections were mounted on Franz diffusion cells and treated with anticancer drugs paclitaxel (PTX) and docetaxel (DTX) formulated in diblock copolymer (methoxy poly(ethylene glycol)-block-poly (D,L-lactic acid) (MePEG-PDLLA) and methoxy poly(ethylene glycol)-block-poly(caprolactone) (MePEG-PCL) nanoparticles for 2 h. The bladder sections were then frozen, cryosectioned (60-μm sections) and the amount of 3H drug taken up into each section was determined using liquid scintillation counting. Tissue concentration versus tissue depth profiles were obtained for all drug formulations and drug exposure obtained from area-under-the-curve (AUC) calculations. PTX or DTX loaded in MePEG-PDLLA micelles produced significantly higher urothelial tissue levels and greater bladder wall exposures compared to their commercial formulations, Cremophor EL/ethanol (PTX) or Tween 80 (DTX). The results of this study support the use of diblock copolymer micellar PTX or DTX formulations as they allow for improved drug penetration of bladder tissues compared to commercial formulations for taxane delivery to superficial bladder tumors.
Literatur
1.
Zurück zum Zitat Au JL, Badalament RA, Wientjes MG, Young DC, Warner JA, Venema PL, Pollifrone DL, Harbrecht JD, Chin JL, Lerner SP, Miles BJ (2001) Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 93:597–604PubMedCrossRef Au JL, Badalament RA, Wientjes MG, Young DC, Warner JA, Venema PL, Pollifrone DL, Harbrecht JD, Chin JL, Lerner SP, Miles BJ (2001) Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 93:597–604PubMedCrossRef
2.
Zurück zum Zitat Au JL, Kalns J, Gan Y, Wientjes MG (1997) Pharmacologic effects of paclitaxel in human bladder tumors. Cancer Chemother Pharmacol 41:69–74PubMedCrossRef Au JL, Kalns J, Gan Y, Wientjes MG (1997) Pharmacologic effects of paclitaxel in human bladder tumors. Cancer Chemother Pharmacol 41:69–74PubMedCrossRef
3.
Zurück zum Zitat Badalament RA, Farah RN (1997) Treatment of superficial bladder cancer with intravesical chemotherapy. Semin Surg Oncol 13:335–341PubMedCrossRef Badalament RA, Farah RN (1997) Treatment of superficial bladder cancer with intravesical chemotherapy. Semin Surg Oncol 13:335–341PubMedCrossRef
4.
Zurück zum Zitat Barlow LJ, McKiernan JM, Benson MC (2009) The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. World J Urol 27:331–335PubMedCrossRef Barlow LJ, McKiernan JM, Benson MC (2009) The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. World J Urol 27:331–335PubMedCrossRef
5.
Zurück zum Zitat Boring CC, Squires TS, Tong T, Montgomery S (1994) Cancer statistics, 1994. CA Cancer J Clin 44:7–26PubMedCrossRef Boring CC, Squires TS, Tong T, Montgomery S (1994) Cancer statistics, 1994. CA Cancer J Clin 44:7–26PubMedCrossRef
6.
Zurück zum Zitat Bouffioux C, Kurth KH, Bono A, Oosterlinck W, Kruger CB, De Pauw M, Sylvester R (1995) Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European organization for research and treatment of cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European organization for research and treatment of cancer genitourinary group. J Urol 153:934–941PubMedCrossRef Bouffioux C, Kurth KH, Bono A, Oosterlinck W, Kruger CB, De Pauw M, Sylvester R (1995) Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European organization for research and treatment of cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European organization for research and treatment of cancer genitourinary group. J Urol 153:934–941PubMedCrossRef
7.
Zurück zum Zitat Burt HM, Zhang X, Toleikis P, Embree L, Hunter W (1999) development of copolymers of poly(DL-lactide) and methoxypolyethylene glycol as micellar carriers of paclitaxel. Colloids Surf B Biointerfaces 16:161–171CrossRef Burt HM, Zhang X, Toleikis P, Embree L, Hunter W (1999) development of copolymers of poly(DL-lactide) and methoxypolyethylene glycol as micellar carriers of paclitaxel. Colloids Surf B Biointerfaces 16:161–171CrossRef
8.
Zurück zum Zitat Chen D, Song D, Wientjes MG, Au JL (2003) Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel. Clin Cancer Res 9:363–369PubMed Chen D, Song D, Wientjes MG, Au JL (2003) Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel. Clin Cancer Res 9:363–369PubMed
9.
Zurück zum Zitat Dalton JT, Wientjes MG, Badalament RA, Drago JR, Au JL (1991) Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res 51:5144–5152PubMed Dalton JT, Wientjes MG, Badalament RA, Drago JR, Au JL (1991) Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res 51:5144–5152PubMed
10.
Zurück zum Zitat De Ascentiis A, De Grazia J, Bowman C, Colombo P, Peppas NA (1995) Mucoadhesion of poly(2-hydroxyethyl methacrylate) is improved when linear poly(ethylene oxide) chains are added to the polymer network. J Control Release 33:197–201CrossRef De Ascentiis A, De Grazia J, Bowman C, Colombo P, Peppas NA (1995) Mucoadhesion of poly(2-hydroxyethyl methacrylate) is improved when linear poly(ethylene oxide) chains are added to the polymer network. J Control Release 33:197–201CrossRef
11.
Zurück zum Zitat Galabova D, Tuleva B, Spasova D (1996) Permeabilization of Yarrowia lipolytica cells by Triton X-100. Enzyme Microb Technol 18:18–22CrossRef Galabova D, Tuleva B, Spasova D (1996) Permeabilization of Yarrowia lipolytica cells by Triton X-100. Enzyme Microb Technol 18:18–22CrossRef
12.
Zurück zum Zitat Gref R, Luck M, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunk T, Muller RH (2000) ‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces 18:301–313PubMedCrossRef Gref R, Luck M, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunk T, Muller RH (2000) ‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces 18:301–313PubMedCrossRef
13.
Zurück zum Zitat Hadaschik BA, ter Borg MG, Jackson J, Sowery RD, So AI, Burt HM, Gleave ME (2008) Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer. BJU Int 101:1347–1355PubMedCrossRef Hadaschik BA, ter Borg MG, Jackson J, Sowery RD, So AI, Burt HM, Gleave ME (2008) Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer. BJU Int 101:1347–1355PubMedCrossRef
14.
Zurück zum Zitat Highley MS, van Oosterom AT, Maes RA, De Bruijn EA (1999) Intravesical drug delivery. Pharmacokinetic and clinical considerations. Clin Pharmacokinet 37:59–73PubMedCrossRef Highley MS, van Oosterom AT, Maes RA, De Bruijn EA (1999) Intravesical drug delivery. Pharmacokinetic and clinical considerations. Clin Pharmacokinet 37:59–73PubMedCrossRef
15.
Zurück zum Zitat Kerec M, Bogataj M, Veranic P, Mrhar A (2005) Permeability of pig urinary bladder wall: the effect of chitosan and the role of calcium. Eur J Pharm Sci 25:113–121PubMedCrossRef Kerec M, Bogataj M, Veranic P, Mrhar A (2005) Permeability of pig urinary bladder wall: the effect of chitosan and the role of calcium. Eur J Pharm Sci 25:113–121PubMedCrossRef
16.
Zurück zum Zitat Knemeyer I, Wientjes MG, Au JL (1999) Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother Pharmacol 44:241–248PubMedCrossRef Knemeyer I, Wientjes MG, Au JL (1999) Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment. Cancer Chemother Pharmacol 44:241–248PubMedCrossRef
17.
Zurück zum Zitat Konsoula R, Barile FA (2005) Correlation of in vitro cytotoxicity with paracellular permeability in Caco-2 cells. Toxicol In Vitro 19:675–684PubMedCrossRef Konsoula R, Barile FA (2005) Correlation of in vitro cytotoxicity with paracellular permeability in Caco-2 cells. Toxicol In Vitro 19:675–684PubMedCrossRef
18.
Zurück zum Zitat Laudano MA, Barlow LJ, Murphy AM, Petrylak DP, Desai M, Benson MC, McKiernan JM (2010) Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy. Urology 75:134–137PubMedCrossRef Laudano MA, Barlow LJ, Murphy AM, Petrylak DP, Desai M, Benson MC, McKiernan JM (2010) Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy. Urology 75:134–137PubMedCrossRef
19.
Zurück zum Zitat Lee WK, Park KD, Kim YH, Suh H, Park JC, Lee JE, Sun K, Baek MJ, Kim HM, Kim SH (2001) Improved calcification resistance and biocompatibility of tissue patch grafted with sulfonated PEO or heparin after glutaraldehyde fixation. J Biomed Mater Res 58:27–35PubMedCrossRef Lee WK, Park KD, Kim YH, Suh H, Park JC, Lee JE, Sun K, Baek MJ, Kim HM, Kim SH (2001) Improved calcification resistance and biocompatibility of tissue patch grafted with sulfonated PEO or heparin after glutaraldehyde fixation. J Biomed Mater Res 58:27–35PubMedCrossRef
20.
Zurück zum Zitat Letchford K, Liggins R, Burt H (2008) Solubilization of hydrophobic drugs by methoxy poly(ethylene glycol)-block-polycaprolactone diblock copolymer micelles: theoretical and experimental data and correlations. J Pharm Sci 97:1179–1190PubMedCrossRef Letchford K, Liggins R, Burt H (2008) Solubilization of hydrophobic drugs by methoxy poly(ethylene glycol)-block-polycaprolactone diblock copolymer micelles: theoretical and experimental data and correlations. J Pharm Sci 97:1179–1190PubMedCrossRef
21.
Zurück zum Zitat Letchford K, Liggins R, Wasan KM, Burt H (2009) In vitro human plasma distribution of nanoparticulate paclitaxel is dependent on the physicochemical properties of poly(ethylene glycol)-block-poly(caprolactone) nanoparticles. Eur J Pharm Biopharm 71:196–206PubMedCrossRef Letchford K, Liggins R, Wasan KM, Burt H (2009) In vitro human plasma distribution of nanoparticulate paclitaxel is dependent on the physicochemical properties of poly(ethylene glycol)-block-poly(caprolactone) nanoparticles. Eur J Pharm Biopharm 71:196–206PubMedCrossRef
22.
Zurück zum Zitat Malmstrom PU (2003) Intravesical therapy of superficial bladder cancer. Crit Rev Oncol Hematol 47:109–126PubMedCrossRef Malmstrom PU (2003) Intravesical therapy of superficial bladder cancer. Crit Rev Oncol Hematol 47:109–126PubMedCrossRef
23.
Zurück zum Zitat McKiernan JM, Masson P, Murphy AM, Goetzl M, Olsson CA, Petrylak DP, Desai M, Benson MC (2006) Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol 24:3075–3080PubMedCrossRef McKiernan JM, Masson P, Murphy AM, Goetzl M, Olsson CA, Petrylak DP, Desai M, Benson MC (2006) Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol 24:3075–3080PubMedCrossRef
24.
Zurück zum Zitat Mugabe C, Hadaschik BA, Kainthan RK, Brooks DE, So AI, Gleave ME, Burt HM (2009) Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy. BJU Int 103:978–986PubMedCrossRef Mugabe C, Hadaschik BA, Kainthan RK, Brooks DE, So AI, Gleave ME, Burt HM (2009) Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy. BJU Int 103:978–986PubMedCrossRef
25.
Zurück zum Zitat Nativ O, Aronson M, Medalia O, Moldavsky T, Sabo E, Ringel I, Kravtsov V (1997) Anti-neoplastic activity of paclitaxel on experimental superficial bladder cancer: in vivo and in vitro studies. Int J Cancer 70:297–301PubMedCrossRef Nativ O, Aronson M, Medalia O, Moldavsky T, Sabo E, Ringel I, Kravtsov V (1997) Anti-neoplastic activity of paclitaxel on experimental superficial bladder cancer: in vivo and in vitro studies. Int J Cancer 70:297–301PubMedCrossRef
26.
Zurück zum Zitat Oosterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R (1993) A prospective European organization for research and treatment of cancer genitourinary group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149:749–752PubMed Oosterlinck W, Kurth KH, Schroder F, Bultinck J, Hammond B, Sylvester R (1993) A prospective European organization for research and treatment of cancer genitourinary group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149:749–752PubMed
27.
Zurück zum Zitat Rangel C, Niell H, Miller A, Cox C (1994) Taxol and taxotere in bladder cancer: in vitro activity and urine stability. Cancer Chemother Pharmacol 33:460–464PubMedCrossRef Rangel C, Niell H, Miller A, Cox C (1994) Taxol and taxotere in bladder cancer: in vitro activity and urine stability. Cancer Chemother Pharmacol 33:460–464PubMedCrossRef
28.
Zurück zum Zitat Shen Z, Shen T, Wientjes MG, O’Donnell MA, Au JL (2008) Intravesical treatments of bladder cancer: review. Pharm Res 25:1500–1510PubMedCrossRef Shen Z, Shen T, Wientjes MG, O’Donnell MA, Au JL (2008) Intravesical treatments of bladder cancer: review. Pharm Res 25:1500–1510PubMedCrossRef
29.
Zurück zum Zitat Soler AP, Miller RD, Laughlin KV, Carp NZ, Klurfeld DM, Mullin JM (1999) Increased tight junctional permeability is associated with the development of colon cancer. Carcinogenesis 20:1425–1431PubMedCrossRef Soler AP, Miller RD, Laughlin KV, Carp NZ, Klurfeld DM, Mullin JM (1999) Increased tight junctional permeability is associated with the development of colon cancer. Carcinogenesis 20:1425–1431PubMedCrossRef
30.
Zurück zum Zitat Song D, Wientjes MG, Au JL (1997) Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother Pharmacol 40:285–292PubMedCrossRef Song D, Wientjes MG, Au JL (1997) Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother Pharmacol 40:285–292PubMedCrossRef
31.
Zurück zum Zitat Sylvester RJ, Oosterlinck W, van der Meijden AP (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171:2186–2190, quiz 2435 Sylvester RJ, Oosterlinck W, van der Meijden AP (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171:2186–2190, quiz 2435
32.
Zurück zum Zitat Tolley DA, Parmar MK, Grigor KM, Lallemand G, Benyon LL, Fellows J, Freedman LS, Hall RR, Hargreave TB, Munson K, Newling DW, Richards B, Robinson MR, Rose MB, Smith PH, Williams JL, Whelan P (1996) The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 155:1233–1238PubMedCrossRef Tolley DA, Parmar MK, Grigor KM, Lallemand G, Benyon LL, Fellows J, Freedman LS, Hall RR, Hargreave TB, Munson K, Newling DW, Richards B, Robinson MR, Rose MB, Smith PH, Williams JL, Whelan P (1996) The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 155:1233–1238PubMedCrossRef
33.
Zurück zum Zitat Tringali G, Lisi L, Bettella F, Renier D, Di Stasi SM, Navarra P (2008) The in vitro rabbit whole bladder as a model to investigate the urothelial transport of anticancer agents The ONCOFID-P paradigm. Pharmacol Res 58:340–343PubMedCrossRef Tringali G, Lisi L, Bettella F, Renier D, Di Stasi SM, Navarra P (2008) The in vitro rabbit whole bladder as a model to investigate the urothelial transport of anticancer agents The ONCOFID-P paradigm. Pharmacol Res 58:340–343PubMedCrossRef
34.
Zurück zum Zitat Wientjes MG, Badalament RA, Au JL (1996) Penetration of intravesical doxorubicin in human bladders. Cancer Chemother Pharmacol 37:539–546PubMedCrossRef Wientjes MG, Badalament RA, Au JL (1996) Penetration of intravesical doxorubicin in human bladders. Cancer Chemother Pharmacol 37:539–546PubMedCrossRef
35.
Zurück zum Zitat Wirth M, Plattner VE, Gabor F (2009) Strategies to improve drug delivery in bladder cancer therapy. Expert Opin Drug Deliv 6:727–744PubMedCrossRef Wirth M, Plattner VE, Gabor F (2009) Strategies to improve drug delivery in bladder cancer therapy. Expert Opin Drug Deliv 6:727–744PubMedCrossRef
36.
Zurück zum Zitat Zhang X, Jackson J, Burt HM (1996) Development of amphiphilic diblock copolymers as micellar carriers of taxol. Int J Pharm 132:195–206CrossRef Zhang X, Jackson J, Burt HM (1996) Development of amphiphilic diblock copolymers as micellar carriers of taxol. Int J Pharm 132:195–206CrossRef
Metadaten
Titel
The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations
verfasst von
Antonia Tsallas
John Jackson
Helen Burt
Publikationsdatum
01.08.2011
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 2/2011
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-010-1499-2

Weitere Artikel der Ausgabe 2/2011

Cancer Chemotherapy and Pharmacology 2/2011 Zur Ausgabe

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.